ICON plc reported third-quarter revenue of $2,024.8 million and adjusted diluted earnings per share of $2.66, a 17% decline from the prior year period but an increase over Q2 2026. The company generated free cash flow of $302.4 million and repurchased $400 million in shares at an average price of $170 per share. Net business wins totaled $3,150 million with a book-to-bill ratio of 1.56x, while the closing backlog reached $24.5 billion. Management updated full-year guidance to expect revenue between $8,100 and $8,200 million and adjusted diluted EPS in the range of $10.35 to $10.65. The Board increased the share repurchase authorization by $350 million, bringing the total available for buybacks to $750 million. ICON plc is a world-leading clinical research organization providing integrated consulting, clinical development, and commercialization solutions.
